Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia
NCT02509546Phase 2Completed
- Sponsor
- City of Hope
- Start
- Oct 2015
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of 8-chloroadenosine in acute myeloid leukemia (AML) (6 arms), sponsored by City of Hope. Primary endpoints: Recommended Phase II Dose at 28 days and Dose Limiting Toxicity at 28 days. Started Oct 2015; status: completed.
02
Drugs
8-chloroadenosine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02509546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509546.